Caseware UK (AP4) 2025.0.111 2025.0.111 2025-12-312025-12-312025-01-01truefalseNo description of principal activity00truefalse 10811735 2025-01-01 2025-12-31 10811735 2024-01-01 2024-12-31 10811735 2025-12-31 10811735 2024-12-31 10811735 c:Director1 2025-01-01 2025-12-31 10811735 d:CurrentFinancialInstruments 2025-12-31 10811735 d:CurrentFinancialInstruments 2024-12-31 10811735 d:CurrentFinancialInstruments d:WithinOneYear 2025-12-31 10811735 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 10811735 d:ShareCapital 2025-12-31 10811735 d:ShareCapital 2024-12-31 10811735 d:RetainedEarningsAccumulatedLosses 2025-12-31 10811735 d:RetainedEarningsAccumulatedLosses 2024-12-31 10811735 c:OrdinaryShareClass1 2025-01-01 2025-12-31 10811735 c:OrdinaryShareClass1 2025-12-31 10811735 c:OrdinaryShareClass1 2024-12-31 10811735 c:FRS102 2025-01-01 2025-12-31 10811735 c:Audited 2025-01-01 2025-12-31 10811735 c:FullAccounts 2025-01-01 2025-12-31 10811735 c:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 10811735 c:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 10811735 e:PoundSterling 2025-01-01 2025-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 10811735










BLUECLINIC LTD










FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

 
BLUECLINIC LTD
REGISTERED NUMBER: 10811735

BALANCE SHEET
AS AT 31 DECEMBER 2025

2025
Unaudited 2024
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
72,104
106,969

Cash at bank and in hand
 5 
518,971
486,962

  
591,075
593,931

Creditors: amounts falling due within one year
 6 
(263,636)
(287,138)

Net current assets
  
 
 
327,439
 
 
306,793

Total assets less current liabilities
  
327,439
306,793

  

Net assets
  
327,439
306,793


Capital and reserves
  

Called up share capital 
  
10
10

Profit and loss account
  
327,429
306,783

  
327,439
306,793


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




M V Peeters
Director

Date: 13 October 2026

The notes on pages 2 to 4 form part of these financial statements.

Page 1

 
BLUECLINIC LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1.


General information

Blueclinic Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number is 10811735 and its registered office address is 167-169 Great Portland Street, 5th Floor, London, W1W 5PF.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of income and retained earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Turnover represents amounts charged to the Company's parent under an agreement for sales and marketing support provided, excluding value added tax. Turnover is recognised when chargeable costs are incurred.

Page 2

 
BLUECLINIC LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.4

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


 
2.5

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.7

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The Company has no employees other than the directors, who did not receive any remuneration (2024 - £NIL).

The average monthly number of employees, including directors, during the year was 0 (2024 - 0).


4.


Debtors

2025
Unaudited 2024
£
£


Other debtors
71,957
101,649

Prepayments and accrued income
147
5,320

72,104
106,969


Page 3

 
BLUECLINIC LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

5.


Cash and cash equivalents

2025
Unaudited 2024
£
£

Cash at bank and in hand
518,971
486,962

518,971
486,962



6.


Creditors: Amounts falling due within one year

2025
Unaudited 2024
£
£

Trade creditors
65,451
56,427

Corporation tax
6,882
-

Other taxation and social security
15,953
33,092

Accruals and deferred income
175,350
197,619

263,636
287,138



7.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



100 (2024 - 100) Ordinary shares of £0.10 each
10
10



8.


Controlling party

The company is a wholly owned subsidiary company of E-Health Ventures Holding B.V. Bijister 18, 4817 HX Breda, Netherlands. A copy of the group accounts are available at the registered address.


9.


Auditor's information

The auditor's report on the financial statements for the year ended 31 December 2025 was unqualified.

The audit report was signed on 13 October 2026 by Jason Mitchell MBA BSc FCA (Senior statutory auditor) on behalf of MHA.

Page 4